Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 806

Sort by

Sort Order Select

Journal Articles

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

Cindy Lynn Hickey, MDFRCPC, David Conrad, MD PhD, Stephen Couban, MDBSc

Blood (2019) 134 (Supplement_1): 1308.

https://doi.org/10.1182/blood-2019-121336

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 823.

https://doi.org/10.1182/blood-2019-125136

Published: 2019

Journal Articles

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Blood (2019) 134 (Supplement_1): 743.

https://doi.org/10.1182/blood-2019-123382

Published: 2019

Journal Articles

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Allison Barz Leahy, MD, Kaitlin J. Stanley, MD, Regina M. Myers, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Susan R. Rheingold, MD, Colleen Callahan, CRNP, Diane Baniewicz, CRNP, Amy E. Barry, PPCNP-BC, Maria M. Patino, BS, Stephen P. Hunger, MD, Stephan Grupp, MD PhD, David M. Barrett, Shannon L. Maude, MD PhD

Blood (2019) 134 (Supplement_1): 1464.

https://doi.org/10.1182/blood-2019-130060

Published: 2019

Journal Articles

Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015

Blood (2019) 134 (Supplement_1): 2576.

https://doi.org/10.1182/blood-2019-128523

Published: 2019

Journal Articles

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Rachael E Hough, MD, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora

Blood (2019) 134 (Supplement_1): 2579.

https://doi.org/10.1182/blood-2019-127223

Published: 2019

Journal Articles

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Jeremy Chang, MD, Sherry Zhang, MD, Mojtaba Akhtari, MD

Blood (2019) 134 (Supplement_1): 2581.

https://doi.org/10.1182/blood-2019-123738

Published: 2019

Journal Articles

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Alessandro Rambaldi, MD, Renato Bassan, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 2627.

https://doi.org/10.1182/blood-2019-122917

Published: 2019

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Yanika Jindamai, MD, Ekarat Rattarittamrong, MD, Arintaya Phrommintikul, MD, Lalita Yongsmith, MD, Thanawat Rattanathammethee, MD, Chatree Chai-Adisaksopha, MD PhD, Adisak Tantiworawit, MD, Lalita Norasetthada, MD

Blood (2019) 134 (Supplement_1): 5390.

https://doi.org/10.1182/blood-2019-126599

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Nahoko Hatsumi, MD, Satoru Takada, MD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhD, Toru Sakura, PhD MD, Hiroshi Handa, MD PhD

Blood (2019) 134 (Supplement_1): 5690.

https://doi.org/10.1182/blood-2019-130590

Published: 2019

Journal Articles

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

Blood (2019) 134 (Supplement_1): 5694.

https://doi.org/10.1182/blood-2019-128031

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Garima Pandey, Nathan Horvat, Narmin E. Amin, Afua A. Akuffo, Christelle Colin, Pearlie K. Epling-Burnette, Gary W. Reuther

Blood (2019) 134 (Supplement_1): 4198.

https://doi.org/10.1182/blood-2019-128937

Published: 2019

Journal Articles

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kathryn G. Roberts, PhD, Koji Sasaki, MD, Yaqi Zhao, MSc, Chunxu Qu, PhD, Zhaohui Gu, PhD, Nitin Jain, MD, Keyur P. Patel, MBBS, PhD, Farhad Ravandi, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Rebecca Garris, MSc, Steven Kornblau, Marina Y Konopleva, MD PhD, Charles G. Mullighan, MBBS, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 1641.

https://doi.org/10.1182/blood-2019-126940

Published: 2019

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

NARROW

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only